George W. Sledge
Caris Life Sciences (United States) · 1,050 works · 45,572 citations · h-index 92
Top works
- Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- Integrated digital error suppression for improved detection of circulating tumor DNA
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
- Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
- Constitutive Activation of NF-κB during Progression of Breast Cancer to Hormone-Independent Growth
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
- Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831